Dr Amit Kumar

MBBS,MD (Gen Medicine,IMS,BHU), DM , DNB(Medical Oncology,TMH,Mumbai ), ECMO, MRCP- SCE ,Medical Oncologist and Hemato Oncologist

[Dr Amit Kumar @dramitpmc]

@drakhilkapoor1 @DrVijayPatil11 @oncology_bg @SuyogCancer @Bipinesh @dranuj16 @ASCOPost @TMC_Varanasi @ISMPOofficial Congratulations @drakhilkapoor1 @DrVijayPatil11 #ASCO24

[Dr Amit Kumar @dramitpmc]

@bhargava611 @KNJobanputra @TataMemorial Congratulations Boss 👏👏👏👍

[Dr Amit Kumar @dramitpmc]

Biomarkers of toxicity in different ADCs @drakhilkapoor1 @KNJobanputra @GlobOncX

[Dr Amit Kumar @dramitpmc]

Now it’s time for Her 2 PET for ADCs. Drugs are evolving, so is Nuclear Medicine. @GlobOncX @KNJobanputra @drakhilkapoor1

[Dr Amit Kumar @dramitpmc]

@KNJobanputra Low dose ADCs unlikely to be beneficial (completely different ball game from Immunotherapy) due to very narrow therapeutic window of ADCs. @GlobOncX @KNJobanputra @drakhilkapoor1

[Dr Amit Kumar @dramitpmc]

@DrVijayPatil11 @DrEzraCohen @VanitaNoronha @Nandinimenon18 Congratulations Sir👍

[Dr Amit Kumar @dramitpmc]

@neerajaiims Congratulations Sir, really a proud moment!

[Dr Amit Kumar @dramitpmc]

Effect of Early Palliative Care on Quality of Life of Advanced Head and Neck Cancer Patients: A Phase III Trial https://t.co/4X9z0D3ADg

[Dr Amit Kumar @dramitpmc]

@VanitaNoronha @DrVijayPatil11 @Nandinimenon18 @SachinD78722095 @TataMemorial Congrats Ma'am; setting a new SOC for palliative head and neck cancer patients👌

[Dr Amit Kumar @dramitpmc]

@DrVijayPatil11 A new SOC in palliative setting; hope for patients who cannot afford IO

[Dr Amit Kumar @dramitpmc]

Congrats Dr Vijay Patil and team; a milestone study on OMCT; new option for LMIC patients @VanitaNoronha @TataMemorial @JyotiBajpai01 @AnantRamaswamy @drakhilkapoor1 @dr_rajapramanik @IJMPOofficial

[Dr (Prof). Vijay Patil @DrVijayPatil11]

Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial https://t.co/t2PhBwXpz3

[Dr Amit Kumar @dramitpmc]

Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial https://t.co/WMvX0VTi9C